A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Mycosis fungoides; Sezary syndrome
- Focus Therapeutic Use
- 18 Sep 2019 Primary endpoint (Objective Response Rate (ORR), Defined as a Confirmed Partial Response (PR) or Complete Response (CR) Using Global Assessment Standard Response Criteria for Mycosis Fungoides and Sezary Syndrome) has been met, according to results published in the Journal of Clinical Oncology.
- 18 Sep 2019 Results published in the Journal of Clinical Oncology
- 29 Aug 2019 Status changed from active, no longer recruiting to completed.